Roche's Tecentriq wins speedy U.S. review in small cell lung cancer

FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann - Copyright ARND WIEGMANN(Reuters)

By Reuters

Published on 05/12/2018 - 07:34•Updated 26/04/2024 - 15:55

Comments

ZURICH (Reuters) - Roche's <ROG.S> Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18.

Wednesday's announcement comes after Roche in September said patients with untreated extensive-stage SCLC, where cancer has spread, lived a median 12.3 months after getting Tecentriq plus chemotherapy, compared to 10.3 months for those on just chemotherapy.

(Reporting by John Miller; editing by Thomas Seythal)

Comments

You might also like